Exclusive Summary

• - Core patents expired long ago; low IP barriers enable rapid multi-country distribution entry.
• - 200 mg once-daily dosing and an aspirin-alternative profile with lower GI bleeding risk support clear differentiation.
• - Massive global need in arterial thrombotic prevention (CVD ~20.5M deaths/year; PAD ~200M patients) underpins steady chronic demand.
• - Limited presence in US/EU guidelines and markets; established use in China/Italy and parts of LATAM/SEA makes it attractive for aspirin-intolerant segments.
• - With CTD, BE, and recognized GMP, registration and tender timelines can be shortened while delivering 60–90% cost savings versus originators.